Abstract: A paddle mixer for evenly and efficiently mixing a volume of aggregate with minimal spillage is described. The paddle mixer includes a first portion, a second portion, a first paddle, and a second paddle. The paddle mixer may include a means for adjustably fixing the first portion to the second portion. The first paddle and the second paddle are arranged on the first portion and the second portion, respectively, such that the first paddle and the second paddle are perpendicular to each other, promoting mixing of the volume of aggregate with a whirlpool effect allowing mixing with minimal spillage. The first paddle and the second paddle may also be arranged perpendicular to each other by the means for adjustably fixing the first portion and the second portion.

Abstract: The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.

Abstract: The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention utilizes recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in a cell, tissue organ or whole organism, thereby producing novel phenotypes. Novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or target gene in an organism when introduced thereto are also provided.

Abstract: This invention is directed to a RNA interference (RNAi) agent and the use of that RNAi agent to treat hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, where the agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some forms of the invention, the agent has more than one effector sequence. Multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.

Abstract: Methods and means are provided for reducing the phenotypic expression of a nucleic acid of interest in eucaryotic cells, particularly in plant cells, by introducing chimeric genes encoding sense and antisense RNA molecules directed towards the target nucleic acid, which are capable of forming a double stranded RNA region by base-pairing between the regions with sense and antisense nucleotide sequence or by introducing the RNA molecules themselves. Preferably, the RNA molecules comprises simultaneously both sense and antisense nucleotide sequence.

Abstract: This invention is directed to a RNA interference (RNAi) agent and the use of that RNAi agent to treat hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The RNAi agents, or constructs for expressing them are utilised to inhibit expression of at least one Hepatitis B virus (HBV) gene, where the agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some forms of the invention, the agent has more than one effector sequence. Multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.

Abstract: The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.

Abstract: The disclosure relates to an RNA interference (RNAi) agent and the use of that RNAi agent to treat chronic pain in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The DNA-directed RNA interference (ddRNAi) agent for inhibiting expression of one or more target sequences in a pain associated gene comprises, one or more effector sequence sequences and effector complement sequences of at least 17 nucleotides in length, wherein the effector sequence is substantially complementary to the predicted transcript of a target sequence within a pain associated gene.

Abstract: Methods and means are provided for reducing the phenotypic expression of a nucleic acid of interest in eucaryotic cells, particularly in plant cells, by introducing chimeric genes encoding sense and antisense RNA molecules directed towards the target nucleic acid, which are capable of forming a double stranded RNA region by base-pairing between the regions with sense and antisense nucleotide sequence or by introducing the RNA molecules themselves. Preferably, the RNA molecules comprises simultaneously both sense and antisense nucleotide sequence.

Abstract: RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.

Abstract: RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.

Abstract: The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.

Abstract: RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.

Abstract: The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.

Abstract: The disclosure relates to an RNA interference (RNAi) agent and the use of that RNAi agent to treat chronic pain in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The DNA-directed RNA interference (ddRNAi) agent for inhibiting expression of one or more target sequences in a pain associated gene comprises, one or more effector sequence sequences and effector complement sequences of at least 17 nucleotides in length, wherein the effector sequence is substantially complementary to the predicted transcript of a target sequence within a pain associated gene.

Abstract: An equipment recovery system for high risk environments such as high wall mine shafts has a vehicle that rides on a track including applications where a push-beam conveyor may serve as the track. The vehicle has a guide to keep it on the track and a hitch for attaching a recovery cable. The vehicle is remotely operated from outside the mine, has a power train for moving the vehicle, an implement for performing tasks, and carries an onboard power source and electrical control boxes to power and control the vehicle and implement. The vehicle may communicate with an outside operator station via an Ethernet cable and may employ and Ethernet extender for that purpose. The vehicle may have a camera to transmit video images. The vehicle may be operated from a high wall miner control center or from an operator station on a self propelled support vehicle.

Abstract: A material and equipment recovery system for high risk environments has a recovery vehicle and surface control station, and a communication link between them, which may be an Ethernet link. The recovery vehicle has an operable recovery implement suitable to its particular application. The surface control station has an operator station from which an operator can operate the recovery vehicle remotely. Cameras on the recovery vehicle provide images for an operator to maneuver the recovery vehicle and monitor systems on the recovery vehicle. The surface control station also has a winch and recovery cable that attaches to the recovery vehicle to retrieve it should it become disabled. An optical alignment device on the surface control station allows alignment of the surface control station to keep the retrieval cable effective. The recovery vehicle and control station have hitch elements and the recovery vehicle can reposition the control station at a site.

Abstract: The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention utilizes recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in a cell, tissue organ or whole organism, thereby producing novel phenotypes. Novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or target gene in an organism when introduced thereto are also provided.

Abstract: Methods and means are provided for reducing the phenotypic expression of a nucleic acid of interest in eucaryotic cells, particularly in plant cells, by introducing chimeric genes encoding sense and antisense RNA molecules directed towards the target nucleic acid, which are capable of forming a double stranded RNA region by base-pairing between the regions with sense and antisense nucleotide sequence or by introducing the RNA molecules themselves. Preferably, the RNA molecules comprises simultaneously both sense and antisense nucleotide sequence.

Abstract: An agricultural implement for towing over fields, for incorporating crop residues into soil, possessing a pair of juxtaposed, substantially parallel, spaced-apart, rotatable shafts, comprising a first forwardly-mounted shaft and a second rearwardly-mounted shaft, each mounted on a frame transversely to a direction of travel of said implement. A plurality of protruding tine members, extending substantially radially outwardly from each of said pair of shafts and longitudinally spaced along each of said pair of shafts, each tine member adapted to rotate about a longitudinal axis of a respective shaft, a tip of each of said tine members when rotating about said respective shaft creating a circular arc, are further provided. The circular arcs of the tine members on one of said pair of shafts interdigitate with a corresponding plurality of circular arcs of said tine members on said other of said pair of shafts.